We Claim:

1. A pharmaceutical composition comprising:
   (a) an antihistaminically-effective amount of epinastine or a pharmaceutically acceptable salt thereof;
   (b) a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof;
   (c) methylephedrine or a pharmaceutically acceptable salt thereof, and
   (d) a pharmaceutically acceptable carrier or excipient.

wherein the composition does not comprise Belladonna.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises 2 mg to 25 mg of epinastine or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises 10 mg to 240 mg of methylephedrine or a pharmaceutically acceptable salt thereof.

4. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition comprises 10 mg to 240 mg of methylephedrine or a pharmaceutically acceptable salt thereof.

5. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises 10 mg to 300 mg of pseudoephedrine or a pharmaceutically acceptable salt thereof.

6. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition comprises 10 mg to 300 mg of pseudoephedrine or a pharmaceutically acceptable salt thereof.

7. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition comprises 10 mg to 300 mg of pseudoephedrine or a pharmaceutically acceptable salt thereof.

8. The pharmaceutical composition according to claim 1, wherein the active ingredients (a), (b), and (c) are formulated for instant release.

9. The pharmaceutical composition according to claim 1, wherein epinastine or a pharmaceutically acceptable salt thereof is formulated for instant release and at least a portion of the methylephedrine or a pharmaceutically acceptable salt thereof or the pseudoephedrine or a pharmaceutically acceptable salt thereof is formulated for sustained release.

10. The pharmaceutical composition according to claim 9, wherein the total amounts of the methylephedrine or a pharmaceutically acceptable salt thereof or the pseudoephedrine or a pharmaceutically acceptable salt thereof are formulated for sustained release.

11. The pharmaceutical composition according to claim 1, wherein the amounts of pseudoephedrine and methylephrine are the same.

12. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a bilayer tablet.

13. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is a bilayer tablet.

14. The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is a bilayer tablet.

15. The bilayer tablet according to claim 12, comprising:

(a) a first layer A, providing for the sustained release of pseudoephedrine and methylephrine or the corresponding pharmaceutical salts thereof; and

(b) a second layer B, providing for the immediate release of epinastine, comprises an antihistaminically-effective amount of epinastine or a pharmaceutically acceptable salt thereof.

16. The bilayer tablet according to claim 12, further comprising a tablet coating C consisting of pharmaceutically acceptable excipients.

17. The bilayer tablet according to claim 13, further comprising a tablet coating C consisting of pharmaceutically acceptable excipients.

18. The bilayer tablet according to claim 14, further comprising a tablet coating C consisting of pharmaceutically acceptable excipients.

19. The bilayer tablet according to claim 15, further comprising a tablet coating C consisting of pharmaceutically acceptable excipients.

20. The bilayer tablet according to claim 15, wherein the first layer A comprises a decongestant-effective amount of pseudoephedrine or a pharmaceutically acceptable salt thereof, and methylephrine or a pharmaceutically acceptable salt thereof, in a matrix of a swellable hydrophilic polymer.

21. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is a capsule.

22. The pharmaceutical composition according to claim 8, wherein the pharmaceutical composition is a capsule.

23. The pharmaceutical composition according to claim 9, wherein the pharmaceutical composition is a capsule.

24. The pharmaceutical composition according to claim 10, wherein the pharmaceutical composition is a capsule.

25. The capsule according to one of claims 21 to 24, wherein the capsule material comprises a compound selected from the group consisting of chitosan and starch, grain powder, oligosaccharides, methacrylic acid-methylacrylate, methacrylic acid-ethylacrylate, hydroxypropylmethylcellulose acetate, hydroxypropylmethylcellulose succinate, hydroxypropylmethylcellulose phthalate, polyvinyl alcohol, water-soluble non-toxic thermoplasts, hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropyl starch, sodium alginate, gelatine, hard gelatine, and pullulan.

26. The capsule according to one of claims 21 to 24, wherein the ingredients are formulated as sustained release and non-sustained release granules.

27. The capsule according to claim 26, wherein the non-sustained granules are coated with a coating comprising a water insoluble polymer, intestinally soluble polymer, paraffin wax, higher alcohol, higher fatty acid, or higher fatty acid ester.

28. The pharmaceutical composition according to claim 1, wherein the ingredients are formulated as granules which are compressed to a tablet.

29. The pharmaceutical composition according to claim 8, wherein the ingredients are formulated as granules which are compressed to a tablet.

30. The pharmaceutical composition according to claim 9, wherein the ingredients are formulated as granules which are compressed to a tablet.

31. The pharmaceutical composition according to claim 10, wherein the ingredients are formulated as granules which are compressed to a tablet.

32. The pharmaceutical composition according to one of claims 28 to 31, wherein the ingredients are formulated as sustained release and non-sustained release granules which are compressed to a tablet.

33. The pharmaceutical composition according to claim 32, wherein the non-sustained release granules are coated with a coating comprising a water insoluble polymer, intestinally soluble polymer, paraffin wax, higher alcohol, higher fatty acid, or higher fatty acid ester.

34. A method of treating seasonal allergic rhinitis, seasonal allergic conjunctivitis, allergic rhinitis, allergic congestion of the Eustachian tubes, other allergic origin diseases treated using antihistamine and decongestant drugs, or cough, cold and flu symptoms in a patient in need of such treatment, the method comprising administering to a patient the pharmaceutical composition according to one of claims 1, 8, 9, or 10.